EMA recommends authorisation of Rasonque for metastatic pancreatic cancer

Synopsis

The active substance in Rasonque, daraxonrasib, is a RAS inhibitor. - The applicant for Rasonque (daraxonrasib) is Revolution Medicines.

Automatically extracted from the original page. This is a short summary, not the full story, and may omit important detail.